A One Year, Local, Open Label, Multicentre Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on BMD and Biochemical Markers of Bone in PMO Pts Between the Ages of 50 and 65 Years.
Phase of Trial: Phase III
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Biomarker; Therapeutic Use
- 29 Jun 2012 Actual patient number changed from 142 to 118 as reported by ClinicalTrials.gov.
- 29 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Jun 2012 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.